# Harmony Biosciences CFO Glenn Reicin Departs; Interim PFO Named

> news · REPORTED · 2026-07-16

On July 16, 2026, Harmony Biosciences announced that CFO Glenn Reicin was stepping down to pursue other opportunities, with SVP and Controller Stephen Mollichella appointed Interim Principal Financial Officer effective the same day; the company simultaneously reaffirmed its Q2 2026 net product revenue guidance.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases, including narcolepsy and other CNS disorders with unmet medical needs.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: biotech
- Primary source: https://www.sec.gov/Archives/edgar/data/0001802665/000110465926084095/hrmy-20260716x8k.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.